NCT00053001View on ClinicalTrials.gov

Thalidomide and Epoetin Alfa in Treating Anemia in Patients With Myelodysplastic Syndrome

PHASE2CompletedINTERVENTIONAL
Timeline

Start Date

June 30, 2001

Study Completion Date

October 31, 2007

Conditions
AnemiaLeukemiaMyelodysplastic SyndromesMyelodysplastic/Myeloproliferative Neoplasms
Interventions
BIOLOGICAL

epoetin alfa

DRUG

thalidomide

Trial Locations (2)

01608

Fallon Clinic at Worcester Medical Center, Worcester

01655

UMASS Memorial Cancer Center - University Campus, Worcester

Sponsors

Lead Sponsor

Fallon Clinic
All Listed Sponsors
lead

Fallon Clinic

INDUSTRY

NCT00053001 - Thalidomide and Epoetin Alfa in Treating Anemia in Patients With Myelodysplastic Syndrome | Biotech Hunter | Biotech Hunter